Manuel Carrondo | Professor
iBET: Instituto de Biologia Experimental e Tecnológica

Chemical Engineer, 1971, Univ. Porto; Master of Sciences (1975) and PhD in (1979) Environmental Engineering, Imperial College of Science and Technology, U. London; Habilitation in, Biochemical Engineering (1991), NOVA-Univ. Nova de Lisboa. Full Professor, Chemical and Biochemical Engineering, Faculty of Sciences and Technology, NOVA- Univ. Nova de Lisboa (1995-present). Founder (1988), earlier president and CEO (currently vice ?president) of iBET ? Institute for Experimental and Technological Biology (www.ibet.pt), founder and board member of the Portuguese Academy of Engineering (1998-2001) and board member of the Euro CASE (Council on Applied Science and Engineering) (1998-2001), chairman of the ESACT - European Society of Animal Cell Technology (ESACT) (1997-2001) and of Medical Biotechnology Section of the European Federation of Biotechnology (EFB) (1999-2001), member and Vice- Chairman of the External Advisory Group ?Cell Factory? (Research Directorate General, European Commission) (1998-2002), Portuguese High Level Representative at EUREKA Programme (1993-1996), member of the Advisory Board of Max-Planck Institute for Dynamics of Complex Technical Systems, Magdeburg (2008-2014), KGI-Keck Graduate Institute, Claremont, California (2007-...), CEVEC Pharmaceuticals, Köln (2007-...), PBS Biotech, California (2009-?), CNIC - Spanish National Center for Cardiovascular Research Carlos III, Spain (2011-2014), Masthercells - Manufacturing Synergies for Therapeutic Cells, Belgium (2012-2014) and Alloksys - Life Sciences BV, Holland (2012-?), OECD - Portuguese representative to the Working Party on Biotechnology, Nanotechnology and Converging Technologies - (2014-...), iNOVA4Health - Advancing Precision Medicine, Portugal, Unit Coordinator ? (2015-?); IBMT - Fraunhofer Institute for Biomedical Engineering, St. Ingbert, Germany, Advisory Board Member - (2016-?). Meeting Chairman of the ESACT 14th Meeting ?Animal Cell Technology: From Vaccines to Genetic Medicine?, Vilamoura, May 1996 and of the ?3rd Recombinant Protein Production Meeting: A comparative view on host physiology", Tavira-Algarve (Portugal), November 2004. Visiting Professor at Carnegie-Mellon Univ. (1981), Massachusetts Institute of Technology - MIT (1984, 1988), Gesellschaft für Biotechnologische Forschung (1989 and 1993), Visiting Professor, COPPE, Univ. Federal do Rio de Janeiro, Brazil (January 2014 - ?). Supervised 32 PhD students (thesis defended) and published over two hundred and thirty papers in refereed international journals; Associate-Editor of Journal of Biotechnology (2000-2016), member of the editorial board of Biotechnology and Bioengineering, Current Gene Therapy and Biotechnology Letters; referee of Biotechnology Progress, Cytotechnology, Applied Microbiology and Biotechnology, Enzyme and Microbial Biotechnology. Key areas of research interest: Animal Cell Technology and its application for human and animal health (http://tca.itqb.unl.pt). Therapeutic and diagnostic recombinant proteins, including fusion proteins; virus like particles and pseudo viruses as vaccination agents and viruses (retro-, adeno-, lenti-, baculo-) as deliverables for gene therapy; cell therapies and stem cells. cGMP pilot plant scale-